<DOC>
	<DOC>NCT02801591</DOC>
	<brief_summary>Observe the clinical efficacy and safety of Recombinant Human Growth Hormone Injection assisted in the treatment of the patients with poor ovarian response in vitro fertilization and embryo transfer.</brief_summary>
	<brief_title>Effect of Recombinant Human Growth Hormone Injection on the Clinical Outcome of POR in Patients Undergoing IVF/ET</brief_title>
	<detailed_description />
	<mesh_term>Hormones</mesh_term>
	<criteria>Female, age 3042 years old. Diagnosis of POR (2011 ESHRE Bologna Standard). At least two previous IVF failure history. Voluntarily to sign the "informed consent". Severe acute and chronic liver and kidney disease，Such as liver cirrhosis, acute and chronic renal failure, hepatitis B virus activity period, etc.；Liver and kidney dysfunction. Endocrine and metabolic diseases，eg, diabetes、Thyroid function hyperthyroidism, Thyroid dysfunction, cushing's syndrome, hyperprolactinemia，hyperandrogenism. Related diseases affecting outcome of IVF pregnancy，eg, hydrosalpinx, hysteromyoma≥4cm, adenomyosis, stage III and IV endometriosis, untreated endometrial lesions, uterine malformation, genital tuberculosis, malignant tumor of reproductive system （include endometrial carcinoma, cervical carcinoma, ovarian cancer, fallopian tube carcinoma）. Allergic to E. coli expression product and its excipients. Subjects who participated in the past three months or are participating in other drug clinical researchers. IVF failure history≥3. The researchers consider who is not suitable for enrolling the group.</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>42 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>